PBYI — PUMA BIOTECHNOLOGY, INC.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2016-01-04.
Performance
Technicals
Others in Healthcare
Measured signals that fired on PBYI
| date | signal | measured base rate |
|---|---|---|
| 2026-08-07 | Breakout to a 52-week high price | -1.00% over 21 days · t = -8.58 · n = 24,386 statistically distinguishable from its control group |
| 2026-07-15 | Equal highs taken out structure | -0.70% over 21 days · t = -8.28 · n = 68,636 statistically distinguishable from its control group |
| 2026-07-13 | Short volume far above its own normal short | -0.76% over 21 days · t = -2.79 · n = 5,897 statistically distinguishable from its control group |
| 2026-06-26 | Breakout to a 52-week high price | -1.00% over 21 days · t = -8.58 · n = 24,386 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-07-06 | AUERBACH ALAN H President and CEO | Open-market sale 10b5-1 plan | 44.1K | 8.26 | 364.1K |
| 2026-07-06 | NOUGUES MAXIMO F Chief Financial Officer | Open-market sale 10b5-1 plan | 9.4K | 8.26 | 77.6K |
| 2026-07-06 | HUNT DOUGLAS M See Remarks | Open-market sale 10b5-1 plan | 8.5K | 8.26 | 69.9K |
| 2026-06-12 | Senderowicz Adrian Director | Open-market sale 10b5-1 plan | 27.0K | 7.20 | 194.3K |
| 2026-06-12 | MOYES JAY M Director | Open-market sale 10b5-1 plan | 22.0K | 7.22 | 158.8K |
| 2026-06-12 | Dorval Allison Director | Open-market sale 10b5-1 plan | 11.6K | 7.20 | 83.6K |
| 2026-06-12 | WILSON TROY EDWARD Director | Open-market sale 10b5-1 plan | 10.8K | 7.20 | 77.7K |
| 2026-06-12 | Stuglik Brian M Director | Open-market sale 10b5-1 plan | 8.1K | 7.20 | 58.3K |
| 2026-06-11 | MILLER MICHAEL PATRICK Director | Grant or award | 27.0K | 0.00 | 0 |
| 2026-06-11 | Senderowicz Adrian Director | Grant or award 10b5-1 plan | 27.0K | 0.00 | 0 |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| ACORN CAPITAL ADVISORS, LLC | 26.4M | 4.1M |
| BlackRock, Inc. | 23.0M | 3.6M |
| RENAISSANCE TECHNOLOGIES LLC | 12.4M | 1.9M |
| AMERICAN CENTURY COMPANIES INC | 12.2M | 1.9M |
| VANGUARD CAPITAL MANAGEMENT LLC | 11.6M | 1.8M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 11.1M | 1.7M |
| MILLENNIUM MANAGEMENT LLC | 9.4M | 1.5M |
| DIMENSIONAL FUND ADVISORS LP | 9.2M | 1.4M |
| O'SHAUGHNESSY ASSET MANAGEMENT, LLC | 7.3M | 1.1M |
| GEODE CAPITAL MANAGEMENT, LLC | 6.5M | 1.0M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
Ask the AI about PBYI
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →